Trial is the first to show a delay in confirmed disability progression in non-relapsing secondary progressive MS

Published Date: 09 Apr 2025

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advances in "next generation" photoactive cancer therapy

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot